11:36 AM EST - Critical Outcome Technologies Inc. : announced important positive results from a series of experiments carried out at a prominent American cancer research facility. The experiments were designed first, to estimate the oral maximum tolerated dose, or MTD, for COTI-2; second, to evaluate the effectiveness of oral COTI-2 alone and third, to compare the effectiveness of oral COTI-2 plus Doxil to that of Doxil alone. Critical Outcome Technologies Inc.
shares V.COT are trading down $0.05 at $0.71.
